+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptide Vaccine for Tumor Market - Global Forecast 2026-2032- Product Image
Peptide Vaccine for Tumor Market - Global Forecast 2026-2032- Product Image
Sale

Peptide Vaccine for Tumor Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6147897
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Peptide Vaccine for Tumor Market is projected to reach USD 2.01 Billion in 2026. It is expected to continue growing at a CAGR of 23.22%, reaching USD 7.05 Billion by 2032.

Peptide Vaccines for Tumors: Executive Overview

Peptide vaccines for tumors are therapeutic immunization approaches that use selected tumor-associated or tumor-specific peptide antigens to stimulate immune recognition. Development remains centered on improving antigen selection, strengthening immune activation, and addressing tumor heterogeneity and immune suppression. Clinical relevance depends on demonstrating durable, clinically meaningful responses alongside acceptable safety and practical manufacturing.

How Precision Immuno-Oncology Is Reshaping Development

The field is shifting from broadly shared antigens toward personalized and neoantigen-informed designs supported by genomic and immunologic profiling. Combination strategies with checkpoint inhibition, adjuvants, cytokine modulation, or conventional treatment are being evaluated to overcome weak immune priming and exhausted tumor-infiltrating lymphocytes. Regulatory and clinical priorities increasingly emphasize biomarker-defined populations, reproducible manufacturing, and endpoints that connect immune activation with patient benefit.

Artificial Intelligence Accelerates Antigen and Trial Decisions

Artificial intelligence can support peptide-vaccine research by ranking candidate epitopes, modeling major histocompatibility complex binding, identifying tumor-specific mutations, and integrating genomic, transcriptomic, and immunologic data. It may also improve patient-selection algorithms, trial recruitment, response monitoring, and manufacturing quality control. These applications require clinically validated datasets, transparent model performance, strong privacy safeguards, and prospective confirmation because computational predictions do not by themselves establish immunogenicity or therapeutic benefit.

Regional Insights Across the Global Development Ecosystem

North America has strong capabilities in cancer immunology, translational research, clinical trials, and advanced diagnostics. Europe benefits from coordinated academic networks, regulatory experience, and public research infrastructure, while Asia-Pacific combines expanding oncology capacity with substantial expertise in biotechnology and precision medicine. Latin America is strengthening research and access capabilities but continues to face uneven infrastructure and trial availability. The Middle East is investing in specialized healthcare, genomics, and innovation programs, whereas Africa’s priorities include diagnostic access, research infrastructure, and equitable participation in oncology development. Across regions, reimbursement, biomarker testing, cold-chain requirements, and regulatory alignment remain important implementation considerations.

Group-Level Patterns: Cooperation, Regulation, and Access

ASEAN markets present varied regulatory systems and healthcare capacity, making regional trial coordination and harmonized evidence requirements valuable. BRICS members contribute large and diverse patient populations, research capabilities, and manufacturing potential, although access and regulatory conditions differ substantially. The European Union benefits from shared scientific and regulatory structures alongside national reimbursement decisions. G7 countries generally provide advanced oncology research and diagnostic ecosystems, while NATO members may support cross-border scientific collaboration and resilient biomedical supply chains. GCC states are developing high-capacity healthcare and genomics programs, with opportunities to connect specialized clinical centers to broader international research networks.

Country-Level Priorities in Research and Clinical Translation

Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, the United States, Japan, South Korea, China, India, Brazil, Mexico, and Russia each offer distinct combinations of oncology expertise, patient populations, clinical infrastructure, and regulatory requirements. The United States and Canada have mature translational ecosystems; European countries contribute specialized academic and clinical networks; Japan and South Korea combine advanced oncology practice with strong biomedical research; China and India provide extensive research and patient-care capacity with evolving precision-medicine systems. Australia supports internationally connected clinical research, while Brazil and Mexico are important Latin American settings for regional studies. Russia’s research and healthcare environment requires careful assessment of regulatory, operational, and collaboration conditions. Country strategies should therefore be tailored rather than treated as interchangeable.

Actions for Leaders: Validate Biology, Integrate Data, and Plan Access

Industry leaders should prioritize well-defined antigens, clinically relevant biomarkers, and trial designs that test whether immune activation translates into meaningful outcomes. Combining peptide vaccines with complementary immunotherapies should be guided by biological rationale and prospective subgroup analysis rather than broad empirical use. Organizations should establish data governance for artificial intelligence, invest in scalable and reproducible manufacturing, and engage regulators and payers early. Partnerships with diagnostic providers, academic centers, and patient groups can improve enrollment, biomarker adoption, and real-world implementation while keeping safety monitoring and equitable access central to development plans.

Research Methodology for a Rigorous Executive Assessment

This executive summary uses a structured review of the peptide-vaccine-for-tumor domain, emphasizing established scientific, clinical, regulatory, and health-system considerations. Evidence should be triangulated across peer-reviewed research, registered clinical trials, regulatory publications, public health sources, and documented manufacturing or diagnostic standards. Findings are organized by technology evolution, artificial intelligence applications, geography, institutional groupings, and country context. Claims should be refreshed as trial results, regulatory decisions, biomarker standards, and access policies change; no market estimates, market shares, forecasts, or company-specific claims are used.

Conclusion: Clinical Proof and Delivery Discipline Will Define Progress

Peptide vaccines for tumors occupy an important intersection of precision oncology, immunology, genomics, and data science. Progress will depend less on antigen design alone than on selecting responsive patients, overcoming the tumor microenvironment, combining therapies rationally, and delivering consistent products through practical care pathways. Leaders that connect validated biology with robust evidence generation, responsible artificial intelligence, regional collaboration, and access planning will be better positioned to translate promising immune concepts into dependable patient outcomes.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Peptide Vaccine for Tumor Market, by Cancer Type
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Lung Cancer
7.5. Melanoma
8. Peptide Vaccine for Tumor Market, by Therapy Type
8.1. Introduction
8.2. Multi-Epitope Vaccine
8.3. Peptide Conjugate Vaccine
8.4. Therapeutic Peptide Vaccine
9. Peptide Vaccine for Tumor Market, by Route Of Administration
9.1. Introduction
9.2. Intramuscular
9.3. Intravenous
9.4. Subcutaneous
10. Peptide Vaccine for Tumor Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Outpatient Clinics
10.2.2. Private Clinics
10.3. Hospitals
10.3.1. General Hospitals
10.3.2. Specialty Hospitals
10.4. Research Institutes
10.4.1. Academic Institutes
10.4.2. Private Research Labs
11. Peptide Vaccine for Tumor Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Peptide Vaccine for Tumor Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Peptide Vaccine for Tumor Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. BioNTech SE
15.2. BrightPath Biotherapeutics Co., Ltd.
15.3. Candel Therapeutics, Inc.
15.4. Elicio Therapeutics, Inc.
15.5. Evaxion Biotech A/S
15.6. Immatics N.V.
15.7. Imugene Limited
15.8. ISA Pharmaceuticals B.V.
15.9. Moderna, Inc.
15.10. Nouscom AG
15.11. OncoTherapy Science, Inc.
15.12. OSE Immunotherapeutics SA
15.13. Scancell Holdings plc
15.14. SELLAS Life Sciences Group, Inc.
15.15. Takis S.r.l.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Peptide Vaccine for Tumor Market, Years Considered for the Study
FIGURE 2. Global Peptide Vaccine for Tumor Market, Research Design
FIGURE 3. Global Peptide Vaccine for Tumor Market, Research Framework
FIGURE 4. Global Peptide Vaccine for Tumor Market, Data Triangulation
FIGURE 5. Global Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Peptide Vaccine for Tumor Market Size, by Cancer Type, 2025 vs 2032 (%)
FIGURE 7. Global Peptide Vaccine for Tumor Market Size, by Cancer Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Peptide Vaccine for Tumor Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 9. Global Peptide Vaccine for Tumor Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Peptide Vaccine for Tumor Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Peptide Vaccine for Tumor Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Peptide Vaccine for Tumor Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Peptide Vaccine for Tumor Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Peptide Vaccine for Tumor Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Peptide Vaccine for Tumor Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Peptide Vaccine for Tumor Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Peptide Vaccine for Tumor Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Peptide Vaccine for Tumor Market Segmentation & Coverage
TABLE 2. Global Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 3. Global Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 4. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 17. Global Multi-Epitope Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Multi-Epitope Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Multi-Epitope Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Peptide Conjugate Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Peptide Conjugate Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Peptide Conjugate Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Therapeutic Peptide Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Therapeutic Peptide Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Therapeutic Peptide Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 27. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 37. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Outpatient Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Outpatient Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Outpatient Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Private Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Private Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Private Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global General Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global General Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global General Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Specialty Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Specialty Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Specialty Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Academic Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Academic Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Academic Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Private Research Labs Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Private Research Labs Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Private Research Labs Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Peptide Vaccine for Tumor Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Peptide Vaccine for Tumor Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 73. North America Peptide Vaccine for Tumor Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. North America Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 75. North America Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 76. North America Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 77. North America Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 78. North America Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 79. North America Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 80. North America Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 81. Latin America Peptide Vaccine for Tumor Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Latin America Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 83. Latin America Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 84. Latin America Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 85. Latin America Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. Latin America Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 87. Latin America Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 88. Latin America Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 89. Europe Peptide Vaccine for Tumor Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Europe Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 91. Europe Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 92. Europe Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 93. Europe Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. Europe Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 95. Europe Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 96. Europe Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 97. Middle East Peptide Vaccine for Tumor Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Middle East Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 99. Middle East Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 100. Middle East Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 101. Middle East Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. Middle East Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 103. Middle East Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 104. Middle East Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 105. Africa Peptide Vaccine for Tumor Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Africa Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 107. Africa Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 108. Africa Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 109. Africa Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. Africa Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 111. Africa Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 112. Africa Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 113. Global Peptide Vaccine for Tumor Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. ASEAN Peptide Vaccine for Tumor Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. ASEAN Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 116. ASEAN Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 117. ASEAN Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 118. ASEAN Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 119. ASEAN Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 120. ASEAN Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 121. ASEAN Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 122. GCC Peptide Vaccine for Tumor Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. GCC Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 124. GCC Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 125. GCC Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 126. GCC Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. GCC Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 128. GCC Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 129. GCC Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 130. European Union Peptide Vaccine for Tumor Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. European Union Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 132. European Union Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 133. European Union Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. European Union Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. European Union Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 136. European Union Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 137. European Union Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 138. BRICS Peptide Vaccine for Tumor Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. BRICS Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 140. BRICS Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 141. BRICS Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 142. BRICS Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. BRICS Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 144. BRICS Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 145. BRICS Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 146. G7 Peptide Vaccine for Tumor Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. G7 Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 148. G7 Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 149. G7 Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 150. G7 Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. G7 Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 152. G7 Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 153. G7 Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 154. NATO Peptide Vaccine for Tumor Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. NATO Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 156. NATO Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 157. NATO Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 158. NATO Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. NATO Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 160. NATO Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 161. NATO Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 162. Global Peptide Vaccine for Tumor Market Size, by Country, 2017-2032 (USD Million)
TABLE 163. United States Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 164. United States Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 165. United States Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 166. United States Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 167. United States Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 168. United States Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 169. United States Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 170. United States Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 171. Canada Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 172. Canada Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 173. Canada Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 174. Canada Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 175. Canada Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 176. Canada Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 177. Canada Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 178. Canada Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 179. Mexico Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 180. Mexico Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 181. Mexico Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 182. Mexico Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 183. Mexico Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. Mexico Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 185. Mexico Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 186. Mexico Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 187. Brazil Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 188. Brazil Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 189. Brazil Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 190. Brazil Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. Brazil Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. Brazil Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 193. Brazil Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 194. Brazil Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 195. United Kingdom Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 196. United Kingdom Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 197. United Kingdom Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 198. United Kingdom Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 199. United Kingdom Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. United Kingdom Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 201. United Kingdom Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 202. United Kingdom Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 203. Germany Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 204. Germany Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 205. Germany Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 206. Germany Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 207. Germany Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Germany Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 209. Germany Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 210. Germany Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 211. France Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 212. France Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 213. France Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 214. France Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 215. France Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. France Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 217. France Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 218. France Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 219. Russia Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 220. Russia Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 221. Russia Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 222. Russia Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 223. Russia Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. Russia Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 225. Russia Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 226. Russia Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 227. Italy Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 228. Italy Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 229. Italy Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 230. Italy Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 231. Italy Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. Italy Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 233. Italy Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 234. Italy Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 235. Spain Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 236. Spain Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 237. Spain Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 238. Spain Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 239. Spain Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 240. Spain Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 241. Spain Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 242. Spain Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 243. China Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 244. China Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 245. China Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 246. China Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 247. China Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. China Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 249. China Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 250. China Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 251. India Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 252. India Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 253. India Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 254. India Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 255. India Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. India Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 257. India Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 258. India Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 259. Japan Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 260. Japan Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 261. Japan Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 262. Japan Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 263. Japan Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 264. Japan Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 265. Japan Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 266. Japan Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 267. Australia Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 268. Australia Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 269. Australia Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 270. Australia Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 271. Australia Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. Australia Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 273. Australia Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 274. Australia Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 275. South Korea Peptide Vaccine for Tumor Market Size, 2017-2032 (USD Million)
TABLE 276. South Korea Peptide Vaccine for Tumor Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 277. South Korea Peptide Vaccine for Tumor Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 278. South Korea Peptide Vaccine for Tumor Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 279. South Korea Peptide Vaccine for Tumor Market Size, by End User, 2017-2032 (USD Million)
TABLE 280. South Korea Peptide Vaccine for Tumor Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 281. South Korea Peptide Vaccine for Tumor Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 282. South Korea Peptide Vaccine for Tumor Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 283. Global Peptide Vaccine for Tumor Market Share, by Key Player, 2025
TABLE 284. Global Peptide Vaccine for Tumor Market, Key Experts

Companies Mentioned

  • BioNTech SE
  • BrightPath Biotherapeutics Co., Ltd.
  • Candel Therapeutics, Inc.
  • Elicio Therapeutics, Inc.
  • Evaxion Biotech A/S
  • Immatics N.V.
  • Imugene Limited
  • ISA Pharmaceuticals B.V.
  • Moderna, Inc.
  • Nouscom AG
  • OncoTherapy Science, Inc.
  • OSE Immunotherapeutics SA
  • Scancell Holdings plc
  • SELLAS Life Sciences Group, Inc.
  • Takis S.r.l.

Related Topics

Related Reports

Cancer Vaccines Market - Global Forecast 2026-2032 - Product Image

Cancer Vaccines Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Neoantigen Cancer Vaccine Market - Global Forecast 2026-2032 - Product Image

Neoantigen Cancer Vaccine Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Peptide Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Peptide Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Neoantigen Cancer Vaccine Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036) - Product Image

Neoantigen Cancer Vaccine Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)

  • Report
  • 289 Pages
  • Global
From
Personalized Cancer Vaccines Market Report 2026 - Product Image

Personalized Cancer Vaccines Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.